CD8A and neoplasm: Thereby, patients with FIGO stage IV exhibited significantly reduced CD8+ T cell proportions in tumor tissues (FIGO III: 30.98 ± 5.16% of CD3+ T cells, FIGO IV: 16.33 ± 3.70% of CD3+ T cells) being visible as trend also for ascites and PB samples (Supplementary Figure 16B).